News Summary: J&J seeks new OK for blood thinner

Associated Press

APPLYING AGAIN: Health giant Johnson & Johnson already has applied to the Food and Drug Administration to be able to sell Xarelto, its clot-preventing drug approved last July, for a fifth use, in patients with heart stents.

SO FAR: Xarelto, part of a new class of blood thinners, is approved for reducing risk of blood clots after knee- or hip-replacement surgery and in patients with a type of irregular heartbeat. Approval is pending for two other uses.

SUCCESSFUL STRATEGY: J&J has pushed sales of some drugs into the billions of dollars by getting approvals for many conditions and patient groups.

Sorry you didn't like this comment. Please provide a reason below.

Are you sure?
Rating failed. Try again.
Request failed. Try again.
We will promote constructive and witty comments to the top, so everyone sees them!
Sorry, we can’t load comments right now. Try again.

    Recommended for You